Evidence map›Paper›PMID 41860948›Full record

ArticleeLife2026

Ex vivo and in vivo CRISPR/Cas9 screenings identify the roles of protein N-glycosylation in regulating T-cell activation and functions.

Yu Hong, Xiaofang Si, Wenjing Liu, Xueying Mai, Yu Zhang

Abstract read
In one paragraph

Article in eLife, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yu Hong *Chinese Institute for Cancer Research, Chinese Institutes for Medical Research, Beijing, China.ORCID https://orcid.org/0009-0009-9899-7139
Xiaofang Si *Chinese Institute for Cancer Research, Chinese Institutes for Medical Research, Beijing, China.ORCID https://orcid.org/0009-0000-5076-1201
Wenjing Liu *Chinese Institute for Cancer Research, Chinese Institutes for Medical Research, Beijing, China.ORCID https://orcid.org/0009-0003-9286-3857
Xueying Mai *Chinese Institute for Cancer Research, Chinese Institutes for Medical Research, Beijing, China.ORCID https://orcid.org/0009-0004-8239-9410
Yu ZhangChinese Institute for Cancer Research, Chinese Institutes for Medical Research, Beijing, China.ORCID https://orcid.org/0000-0002-4888-5923

Funding

National Key Research and Development Program of China 2021YFA1101002National Natural Science Foundation of China 81572795National Natural Science Foundation of China 81773304the "Hundred, Thousand and Ten Thousand Talent Project" by Beijing municipal government 2019A39
6 · The paper itself

Abstract

Cytotoxic CD8

Indexed as

CD8-Positive T-LymphocytesCRISPR-Cas SystemsLymphocyte ActivationAnimalsGalactosyltransferasesGlycosylationHumansMiceReceptors, Antigen, T-Cellbeta-1,4-galactosyltransferase IGalactosyltransferasesReceptors, Antigen, T-CellB4GALT1beta 1,4-galactosyltransferase 1CRISPR/Cas9 screeninggalactosylationimmunologyinflammationmouseT-cell receptortumor immunotherapy

Identifiers

PMID41860948
PMCPMC13004595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.